Amazon Biotech, Inc: Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier
14th Nov 2006, 14:16 GMT
NEW YORK, NY (MARKET WIRE) Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) today announced that its distributor in the Philippines, Union Bless Herbal Products, is applying for an amendment to its current approved drug import license, in order to include Amazon as an approved supplier.
Amazon Biotech, Inc: Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier related news:
- Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier — ArriveNet : Health
- CybeRelease: Philippines Company to Import Amazon Biotech's AIDS Drug — WebWire - Recent Headlines
- CybeRelease: (OTC: AMZB) Gets HIV/AIDS Pact — WebWire - Recent Headlines
- Investor Notice: KGS Announces Investigation on Behalf of Investors in Bodisen Biotech, Inc. — ArriveNet : Press Releases
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech — Market Wire - Pharmaceuticals and Biotech
- BioTech Medics, Inc.: BioTech Medics Announces Pinksheets Quotation — Market Wire - Medical and Healthcare
- The Rosen Law Firm Announces Investigation of Securities Claims Against Bodisen Biotech, Inc. — ArriveNet : Press Releases
- Packaging products supplier reaps awards — Jobwerx.com
- Zydus Cadila files drug application to treat obesity — NewKerala Business India News
- Eugene Science Signs Major Distribution Agreement With RexGene Biotech — ArriveNet : Press Releases
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech